Participant-reported outcome
hypoglycaemia, nausea, diabetes
HYPOGLYCAEMIA, DIABETES
The PRO demonstrated that after completing the study, the vast majority of participants would use low-dose dasiglucagon in their future daily diabetes management if available; 96% responded that they were either very likely (88%) or likely (8%) to use dasiglucagon as part of their routine hypoglycaemia management, whereas 4% (one person) and none answered that this was unlikely (due to nausea) or very unlikely, respectively (